A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes

Sponsor:

Syndax Pharmaceuticals, Inc.

Sponsor Study ID:

SNDX-5613-0708

CTO #:

103998

NCT Number:

NCT06226571

Phase:

I/II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Myeloid and Monocytic Leukemia

Study Objectives:

A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)

---

Request more information